NO20043611L - Fremgangsmate for fremstilling av HMG-COA reduktaseinhibitorer - Google Patents

Fremgangsmate for fremstilling av HMG-COA reduktaseinhibitorer

Info

Publication number
NO20043611L
NO20043611L NO20043611A NO20043611A NO20043611L NO 20043611 L NO20043611 L NO 20043611L NO 20043611 A NO20043611 A NO 20043611A NO 20043611 A NO20043611 A NO 20043611A NO 20043611 L NO20043611 L NO 20043611L
Authority
NO
Norway
Prior art keywords
hmg
preparation
coa reductase
reductase inhibitors
sub
Prior art date
Application number
NO20043611A
Other languages
English (en)
Other versions
NO327091B1 (no
Inventor
Murat Acemogulu
Bernhard Riss
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20043611L publication Critical patent/NO20043611L/no
Publication of NO327091B1 publication Critical patent/NO327091B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår en fremgangsmåte for fremstilling av en forbindelse med formel. eller et salt, særlig et farmasøytisk akseptabelt salt med en base, derav eller et lakton derav hvori element representerer -CH-CH- eller -CH=CH- og R representerer en cyklisk rest.
NO20043611A 2002-01-31 2004-08-30 Fremgangsmate for fremstilling av en enantiomerisk ren form eller en racemisk form av HMG-COA reduktaseinhibitorer NO327091B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35378702P 2002-01-31 2002-01-31
PCT/EP2003/000954 WO2003064392A1 (en) 2002-01-31 2003-01-30 Process for the manufacture of hmg-coa reductase inhibitors

Publications (2)

Publication Number Publication Date
NO20043611L true NO20043611L (no) 2004-08-30
NO327091B1 NO327091B1 (no) 2009-04-20

Family

ID=27663254

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043611A NO327091B1 (no) 2002-01-31 2004-08-30 Fremgangsmate for fremstilling av en enantiomerisk ren form eller en racemisk form av HMG-COA reduktaseinhibitorer

Country Status (22)

Country Link
US (2) US7371865B2 (no)
EP (1) EP1472228B1 (no)
JP (1) JP4524111B2 (no)
KR (1) KR20040081161A (no)
CN (1) CN1305853C (no)
AT (1) ATE426594T1 (no)
AU (1) AU2003226971B2 (no)
BR (1) BR0307303A (no)
CA (1) CA2472776C (no)
CO (1) CO5601005A2 (no)
DE (1) DE60326819D1 (no)
EC (1) ECSP045214A (no)
ES (1) ES2323267T3 (no)
IL (1) IL162980A (no)
MX (1) MXPA04007396A (no)
NO (1) NO327091B1 (no)
NZ (1) NZ534232A (no)
PL (1) PL370658A1 (no)
PT (1) PT1472228E (no)
RU (1) RU2299196C2 (no)
WO (1) WO2003064392A1 (no)
ZA (1) ZA200405322B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101219992B (zh) 2003-02-12 2011-08-31 日产化学工业株式会社 匹伐他汀钙的晶形
KR20060006052A (ko) * 2003-04-24 2006-01-18 다이셀 가가꾸 고교 가부시끼가이샤 에틸(3ｒ,5ｓ,6ｅ)-7-[2-시클로프로필-4-(4-플루오로페닐)퀴놀린-3-일]-3,5-디히드록시-6-헵테노에이트의 제조 방법
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
EP1817027A2 (en) * 2004-09-27 2007-08-15 Ranbaxy Laboratories Limited Process for preparating enantiomerically pure fluvastatin sodium and a novel polymorphic form thereof
US8455640B2 (en) * 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
US8404841B2 (en) * 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
EP2093230A1 (en) * 2007-04-18 2009-08-26 Teva Pharmaceutical Industries Ltd. A process for preparing intermediates of HMG-CoA reductase inhibitors
US20090069563A1 (en) * 2007-07-12 2009-03-12 Valerie Niddam-Hildesheim Rosuvastatin intermediates and their preparation
EP2387561A4 (en) * 2009-01-19 2012-07-25 Msn Lab Ltd IMPROVED METHOD FOR THE PRODUCTION OF HIGH-PURITY (3R, 5S) -7- [2-CYCLOPROPYL-4- (4-FLUORPHENYL) CHINOLIN-3-YL] -3,5-DIHYDROXY-6 (E) -HEPTENIC ACID AND PHARMACEUTICAL ACCEPTABLE SALTS THEREOF
KR101160152B1 (ko) * 2009-02-24 2012-06-27 한미사이언스 주식회사 스타틴 화합물 또는 그 염의 신규 제조방법, 및 이에 사용되는 중간체 화합물
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
US8759518B2 (en) * 2010-02-23 2014-06-24 Cadila Healthcare Limited Intermediates for the preparation of HMG CoA reductase inhibitors and processes for the preparation thereof
EP2383260A3 (en) 2010-04-30 2011-12-28 Dipharma Francis S.r.l. Process for the preparation of statins
WO2011141934A1 (en) 2010-05-13 2011-11-17 Matrix Laboratories Ltd. An improved process for the preparation of an intermediate of hmg-coa reductase inhibitors
CN105153010B (zh) * 2010-07-01 2018-06-08 柳韩洋行 HMG-CoA还原酶抑制剂及其中间体的制备方法
US8912333B2 (en) * 2010-11-12 2014-12-16 Hetero Research Foundation Polymorphs of pitavastatin calcium
CN104066846B (zh) 2011-11-28 2018-09-25 迈兰实验室有限公司 采用南极假丝酵母脂肪酶b制备手性他汀侧链中间体的方法
CN103288871A (zh) * 2012-02-28 2013-09-11 浙江京新药业股份有限公司 一种制备二羟基酸HMG-CoA还原酶抑制剂用的中间体及其制备方法和应用
ITVI20130039A1 (it) 2013-02-20 2014-08-21 F I S Fabbrica Italiana Sint I S P A Processo per la preparazione di intermedi chiave per la sintesi di statine
CN103172656B (zh) * 2013-04-02 2015-07-08 浙江科技学院 3-二甲基叔丁基硅氧基戊二酸酐的合成工艺
CN111518035A (zh) * 2020-06-18 2020-08-11 安徽鼎旺医药有限公司 一种瑞舒伐他汀叔丁胺盐及其制备方法
CN113683539B (zh) * 2021-09-23 2023-05-16 上海裕兰生物科技有限公司 一种聚酮中间体的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4650890A (en) * 1984-04-03 1987-03-17 Sandoz Corp. Preparation of olefinic compounds and intermediates thereof
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US4804770A (en) 1988-04-29 1989-02-14 E. R. Squibb & Sons, Inc. Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
DE3911064A1 (de) * 1989-04-06 1990-10-11 Bayer Ag Substituierte 1,8-naphthyridine
US5049577A (en) * 1990-01-29 1991-09-17 E. R. Squibb & Sons, Inc. 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
ATE123020T1 (de) * 1990-05-11 1995-06-15 American Cyanamid Co N-acylierte arylpyrrole als insektizide, akarizide, nematizide und molluskizide wirkstoffe.
JP3528186B2 (ja) 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
HUP0303555A3 (en) * 2000-11-16 2005-08-29 Teva Pharma Hydrolysis of [r(r
AU2002228413B8 (en) * 2001-02-02 2007-03-22 Mitsubishi Chemical Corporation Process for producing (3R,5S)-(E)-7-[2-Cyclopropyl-4-(4-Fluorophenyl)-Quinolin-3-yl]-3,5-Dihydroxyhept -6-enic acid esters
PT1466905E (pt) * 2001-11-14 2011-07-14 Nissan Chemical Ind Ltd Processo para a produção de éster do ácido oxo-heptenóico opticamente activo
US6835838B2 (en) * 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
GB0210234D0 (en) * 2002-05-03 2002-06-12 Novartis Ag Process for the manufacture of organic compounds

Also Published As

Publication number Publication date
AU2003226971B2 (en) 2006-11-30
NO327091B1 (no) 2009-04-20
CN1305853C (zh) 2007-03-21
EP1472228B1 (en) 2009-03-25
CN1622937A (zh) 2005-06-01
RU2299196C2 (ru) 2007-05-20
PT1472228E (pt) 2009-06-24
KR20040081161A (ko) 2004-09-20
CA2472776A1 (en) 2003-08-07
MXPA04007396A (es) 2004-10-11
IL162980A (en) 2010-02-17
PL370658A1 (en) 2005-05-30
NZ534232A (en) 2006-03-31
JP4524111B2 (ja) 2010-08-11
CO5601005A2 (es) 2006-01-31
ATE426594T1 (de) 2009-04-15
RU2004126442A (ru) 2005-06-10
JP2005520814A (ja) 2005-07-14
HK1070651A1 (en) 2005-06-24
BR0307303A (pt) 2005-01-11
EP1472228A1 (en) 2004-11-03
CA2472776C (en) 2011-01-25
US20080182873A1 (en) 2008-07-31
DE60326819D1 (de) 2009-05-07
WO2003064392A1 (en) 2003-08-07
US7371865B2 (en) 2008-05-13
ZA200405322B (en) 2005-07-27
US20050070605A1 (en) 2005-03-31
ECSP045214A (es) 2004-09-28
ES2323267T3 (es) 2009-07-10

Similar Documents

Publication Publication Date Title
IL162980A (en) Process for the manufacture of hmg-coa reductase inhibitors
EA201200954A1 (ru) Способ получения полугидрата гидрохлорида (r)-8-хлор-1-метил-2,3,4,5-тетрагидро-1н-3-бензазепина, фармацевтическая композиция на его основе и его применение
WO2005046589A3 (en) Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
MA27624A1 (fr) Procede pour realiser une preparation enrobee
CA2506016A1 (en) 3-amino-piperidine derivatives and processes for their preparation
EP2308828A3 (en) CaSR antagonist
WO2004082822A3 (en) Methods for isolating crystalline form i of 5-azacytidine
EP2299508A3 (en) Organic photosensitive optoelectronic device having a phenanthroline exciton blocking layer
EP2292209A3 (en) Stable pharmaceutical composition comprising a pyramidine-sulfamide
EA200400491A1 (ru) Полиморфная форма римонабанта, способ её получения и содержащие её фармацевтические композиции
WO2004096134A3 (en) Substituted 1,4-diazepines and uses thereof
EA200500862A1 (ru) Синоменин и соединения синоменина, синтез и применение
EP1975164A3 (en) Octahydrobenzimidazolone compounds as analgetics
EA200400467A1 (ru) Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора
EA200301120A1 (ru) Цитрат 5,8,14-триазатетрацикло (10.3.1.0.0)-гексадека-2 (11),3,5,7,9-пентаена
MXPA05013584A (es) Compuesto amina terciaria ciclica.
ATE503746T1 (de) Neue imidazolidinderivate
MY138826A (en) 2,7-substituted indoles
ATE429429T1 (de) Pharmazeutisches verfahren und damit hergestellte verbindungen
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
ATE516031T1 (de) Verbindungen gegen krebs
EP2266971A3 (en) Hiv protease inhibiting compounds
NO20062656L (no) Fremgangsmate for fremstilling av statiner
ATE308540T1 (de) Antithrombosemittel
WO2005005394A3 (en) Thiophenylaminoimidazolines as prostaglandin i2 antagonists

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees